A Study of Fifty Cases of Syphilis Treated with Salvarsan, with Special Reference to the Clinical Result and the Wassermann Reaction (reprinted from the New York Medical Journal, 16 and 23 September 1911) (1911)

Peer-Reviewed Study · Abr. L. Wolbarst, M.D. (New York) · September 16, 1911

Abr. L. Wolbarst et al., 1911-09-16: A contemporaneous 50-case series by the physician who gave the first Salvarsan injection in the United States (10 October 1910, 'through the courtesy of Geheimrat Professor Paul Ehrlich'). It records one case of total blindness in a patient whose optic atrophy was already advancing, one case of peroneal paralysis and sciatic neuritis after a second injection, and no deaths attributed to the drug; the author explicitly declines to ascribe the blindness to Salvarsan alone.

In not a single instance was a normal eye affected by the drug, and in only one case (xlii), the existing optic atrophy was apparently stimulated in its progress and total blindness ensued.

p. 3

Abr. L. Wolbarst et al., 1911-09-16: A contemporaneous 50-case series by the physician who gave the first Salvarsan injection in the United States (10 October 1910, 'through the courtesy of Geheimrat Professor Paul Ehrlich'). It records one case of total blindness in a patient whose optic atrophy was already advancing, one case of peroneal paralysis and sciatic neuritis after a second injection, and no deaths attributed to the drug; the author explicitly declines to ascribe the blindness to Salvarsan alone. Funder: none stated; author's own private and hospital practice. Conflicts: none declared in the text. Maker: Salvarsan supplied by Ehrlich/Hoechst ('through the courtesy of Geheimrat Professor Paul Ehrlich'). Comparator: none – uncontrolled case series, no placebo, no untreated control; follow-up averaged about seven months. Efficacy record in the same document (p. 4, verbatim): 'seventy-four per cent, of the patients treated were either "cured" clinically or greatly improved, without a recurrence lasting over a period averaging about seven months.' "Cure" here is clinical only and ignores the Wassermann reaction. The book's blanket claim that Salvarsan 'caused blindness' is supported only in the narrow sense of this single already-atrophic case; the author himself disputes causation. Study type: uncontrolled series.